MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway

aDepartment of Gynecology 1, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University

bDepartment of Biochemistry and Molecular Biology, Shanxi Medical University

cDepartment of Gynecology, Shanxi Medical University

dDepartment of Biotherapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China

Received 5 May 2022 Revised form accepted 9 May 2022

*Dr. Xiaoyan Wang and Dr. Hong Zhao contributed equally to the writing of this article.

Correspondence to Yanling Yu, MM, Department of Biotherapy, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, 3 zhigongxin Street, Xinghualing District, Taiyuan, Shanxi, China, Tel: +13503503393; e-mail: [email protected]

留言 (0)

沒有登入
gif